These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30503378)

  • 1. Physiologically-Based Pharmacokinetic model for Ciprofloxacin in children with complicated Urinary Tract Infection.
    Balbas-Martinez V; Michelet R; Edginton AN; Meesters K; Trocóniz IF; Vermeulen A
    Eur J Pharm Sci; 2019 Feb; 128():171-179. PubMed ID: 30503378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection.
    Meesters K; Michelet R; Mauel R; Raes A; Van Bocxlaer J; Vande Walle J; Vermeulen A
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
    Sadiq MW; Nielsen EI; Khachman D; Conil JM; Georges B; Houin G; Laffont CM; Karlsson MO; Friberg LE
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):69-79. PubMed ID: 27578330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics/Pharmacodynamics (PK/PD) of Ciprofloxacin in the Complicated Urinary Tract Infection (cUTI) Model in Diabetic Mice.
    Reniguntla MK; Yedle R; Puttaswamy R; Puttarangappa P; Hiremath S; Pawar A; Nanjundappa M; Jayaraman R
    Curr Drug Metab; 2020; 21(2):132-139. PubMed ID: 32156232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
    Kawaguchi N; Katsube T; Echols R; Wajima T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29038272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal Impairment.
    Zhuang L; Wu K; Jang SH; Reynolds KS; Mishra S; Iarikov D
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0207421. PubMed ID: 35258314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
    Talan DA; Klimberg IW; Nicolle LE; Song J; Kowalsky SF; Church DA
    J Urol; 2004 Feb; 171(2 Pt 1):734-9. PubMed ID: 14713799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
    Rasool MF; Khalil F; Läer S
    Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.
    Schlender JF; Teutonico D; Coboeken K; Schnizler K; Eissing T; Willmann S; Jaehde U; Stass H
    Clin Pharmacokinet; 2018 Dec; 57(12):1613-1634. PubMed ID: 29737457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Clinical Assessment of the Antimicrobial Activity of Finafloxacin Compared to Ciprofloxacin in Subsets of Microbiologically Characterized Isolates.
    Vente A; Bentley C; Lückermann M; Tambyah P; Dalhoff A
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ciprofloxacin in pediatric patients.
    Rajagopalan P; Gastonguay MR
    J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.
    Waugh J; Keating GM
    Drugs Aging; 2004; 21(1):55-64; discussion 65-6. PubMed ID: 14715044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
    Xiao AJ; Huntington JA; Long J; Caro L
    Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
    Peterson J; Kaul S; Khashab M; Fisher AC; Kahn JB
    Urology; 2008 Jan; 71(1):17-22. PubMed ID: 18242357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance and pharmacokinetics of ciprofloxacin in the chick. Preliminary experience in subjects of pediatric age with urinary tract infections (UTI).
    Naccari F; Salpietro DC; De Sarro A; Masaracchio A; Barberi I
    Res Commun Mol Pathol Pharmacol; 1998 Feb; 99(2):187-92. PubMed ID: 9583092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
    Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
    Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.
    Zimmermann ES; de Miranda Silva C; Neris C; Torres BGDS; Schmidt S; Dalla Costa T
    Eur J Pharm Sci; 2019 Jan; 127():319-329. PubMed ID: 30423435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.